Twitter | Search | |
Search Refresh
Regeneron 16h
The FDA has accepted our supplemental Biologics License Application for our investigational in advanced (). Learn more: CC:
Reply Retweet Like
Krishna “Wear a damn mask” Komanduri 🇺🇸 36m
All true. We need to increase referrals and improve efficiencies and outcomes at each step.
Reply Retweet Like
qimrberghofer 24h
Spring magazine out now! Research updates on -19, treatment & a cancer trial led by who is featured on the beautiful cover designed by Read here:
Reply Retweet Like
SU2Cscience Oct 27
FUNDING OPPORTUNITY: International Waldenstrom’s Macroglobulinemia Foundation Career Development Awards: $150,000 over 2 years, appl'ns due Jan 14 2021. Topics are genomics/epigenomics, signaling, , tumor microenvironment, + more
Reply Retweet Like
IC-ONC Global 5h
Olaparib Monotherapy or in Combination with Bevacizumab FDA approved for Maintenance Treatment of Patients with Advanced Ovarian Cancer
Reply Retweet Like
Oncology Times Oct 28
Reply Retweet Like
Kendall A. Smith 9h
Chapter-1 of my new book, "The Quest for New Knowledge" is now out on my Newsletter, @
Reply Retweet Like
Steven Artandi, MD, PhD 6h
I am pleased to announce our next Frontiers in Oncology seminar featuring 's Chief of Surgery, Dr. Steven Rosenberg, on Tues 11/3/20, 8-9AM. Join us on Zoom: passcode: 059948
Reply Retweet Like
PeerView Oct 28
Cancer and web broadcast still available! To fully participate in polling and claim credit, please visit:
Reply Retweet Like
Journal of European CME Oct 27
New article in the Special Collection - Feasibility of Integrating a Mobile Decision-Support App into a Multicomponent Initiative: Developing Clinician Competence at the Point of Care:
Reply Retweet Like
Immunology 19h
The immunosuppressive action of is a major challenge in cancer , but can we disable Tregs without causing severe immune toxicity? Researchers at discuss a new modality to reprogram Tregs within 👉
Reply Retweet Like
Eileen Parkes Oct 26
Really pleased to share our work out today in - we identified RANTES, CCL5, as an independent prognostic factor in pancreatic cancer - targeting this pathway may be of potential clinical benefit.
Reply Retweet Like
Malaghan Institute Oct 27
We're thrilled that have renewed their support of our CAR T-cell programme, pledging a further $600,000 over the next 3 years
Reply Retweet Like
Zihai Li, MD, PhD Oct 24
I have been blown away by the quality of research and passion of a whole bunch of our recent faculty candidates. Expect the team of warriors to get significantly bigger in 2021. I am ready to turn the page and start dreaming.
Reply Retweet Like
Immunotherapy: Open Access 14h
Immunotherapy seeks to improve the body’s immune response to a tumor
Reply Retweet Like
LakshmiLotus 36m
After weeks of appeals with insurance, yesterday my husband was approved and administered for stage IV . -649 we are praying you work.
Reply Retweet Like
Abhi Acharya Oct 28
Check out this cool webinar by Prof Thomas on look out for the link, will be posted soon!
Reply Retweet Like
Nanobot  Medical  Animation  Studio Oct 26
A medіcal explainer is a useful tool for clarifyіng many vital topіcs, procedures and methods that are often difficult to understand without a good visualisation. Our case study dedicated to immunotherapy:
Reply Retweet Like
Immunotherapy: Open Access Oct 28
CD8+ T cells have the potential to influence the outcome of cancer pathogenesis, including complete tumor eradication or selection of malignant tumor escape variants
Reply Retweet Like
The ASCO Post Oct 28
Association of Tumor Mutational Burden With Response to Pembrolizumab in Previously Treated Patients With Advanced Solid Tumors
Reply Retweet Like